Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ReShape Lifesciences Inc. (OBLN)
|
Add to portfolio |
|
|
|
| Price: |
$2.60
| | Metrics |
| OS: |
3.45
|
M
| |
|
|
| Market cap: |
$8.98
|
M
| |
|
|
|
Net cash:
|
$4.57
|
M
| |
$1.32
|
per share
|
|
EV:
|
$4.41
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 13.6 | 11.3 | 3.3 | 9.1 | 9.9 | 3.4 | 4.0 | 3.5 |
| Revenue growth | 20.4% | 244.4% | -63.9% | -8.2% | 192.2% | -16.0% | 14.1% | |
| Cost of goods sold | 5.3 | 5.0 | 3.0 | 5.4 | 4.8 | 2.8 | 2.5 | 2.9 |
| Gross profit | 8.3 | 6.3 | 0.3 | 3.7 | 5.1 | 0.6 | 1.5 | 0.6 |
| Gross margin | 61.4% | 55.4% | 10.1% | 40.4% | 51.3% | 17.2% | 38.0% | 17.7% |
| Selling, general and administrative | 33.6 | 15.2 | 16.7 | 29.9 | 28.8 | 10.2 | 3.5 | 4.7 |
| Research and development | 2.5 | 3.5 | 6.9 | 10.7 | 10.6 | 9.9 | 13.0 | 5.8 |
| General and administrative | 24.4 | 10.5 | | | | | | |
| EBITA | -26.0 | -10.8 | -23.2 | -37.0 | -34.4 | -19.5 | -14.9 | -9.8 |
| EBITA margin | -191.3% | -95.6% | -708.0% | -406.2% | -346.9% | -574.9% | -369.7% | -278.0% |
| Amortization of intangibles | 1.7 | 1.7 | | | | | | |
| EBIT | -27.7 | -12.5 | -23.2 | -37.0 | -34.4 | -19.5 | -14.9 | -9.8 |
| EBIT margin | -204.0% | -110.2% | -708.0% | -406.2% | -346.9% | -574.9% | -369.7% | -278.0% |
| Pre-tax income | -62.0 | -21.8 | -23.7 | -37.4 | -34.8 | -20.5 | -15.6 | -9.9 |
| Income taxes | -0.1 | -0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.2% | 0.8% | | | | | 0.1% | |
| Net income | -61.9 | -21.6 | -23.7 | -37.4 | -34.8 | -20.5 | -15.6 | -9.9 |
| Net margin | -455.4% | -191.4% | -721.6% | -410.7% | -350.7% | -603.2% | -385.2% | -279.5% |
| |
| Diluted EPS | ($5.00) | ($5.54) | ($5.03) | ($19.64) | ($2.08) | ($4.85) | ($27.14) | ($18.61) |
| Shares outstanding (diluted) | 12.4 | 3.9 | 4.7 | 1.9 | 16.7 | 4.2 | 0.6 | 0.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|